Medtronic, a global leader in healthcare technology, today announced that Dr. Goran Petrovski M.D., Ph.D. has joined the company’s Diabetes Operating Unit as Medical Affairs Director. Dr. Petrovski will play a key role in shaping the clinical evidence strategy and product design for our diabetes technologies and will help strengthen the company’s presence in Central Europe, Middle East and Africa.

Dr. Petrovski has over 20 years of experience as an endocrinologist and diabetologist, has served as a Professor of the University Clinic of Endocrinology/Medical Faculty in Skopje, Macedonia, and Weill Cornell Medicine, Qatar, and is an influential voice among global diabetes societies. He has published over 100 papers in peer-reviewed journals, written or co-written 8 books on type 1 diabetes and has been vocal on the use of technologies such as advanced hybrid closed loop therapy (AHCL) and Smart Multiple Daily Injection (MDI) systems. Most recently he was the Senior attending physician at Sidra Medicine, Weill Cornell University in Doha, Qatar.

“Medtronic shares Dr. Petrovski’s passion and commitment to helping people with diabetes across the globe and we are privileged to welcome such a renowned expert to our team. We look forward to his contribution to our innovation and evidence strategy” said Dr. Robert Vigersky, MD, Chief Medical Officer for Medtronic Diabetes.

About the Diabetes Business at Medtronic (www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results. Dr. Petrovski is being retained by Medtronic as an independent contractor. 

Contacts:

Ashley Patterson
Public Relations
+1-818-576-3025

Ryan Weispfenning
Investor Relations
+1-763-505-4626